Last updated: February 14, 2026
Key Insights for Patentability, Enforceability, and Claim Scope of Biopharmaceutical Patents in Portugal
Patentability Criteria in Portugal
Novelty:
To qualify for patent protection, a biopharmaceutical invention must be new. Any prior publication, public use, or commercial exploitation before the patent filing date invalidates novelty. Prior art searches should encompass European Patent Office (EPO) and World Intellectual Property Organization (WIPO) databases, as Portugal adheres to the European Patent Convention (EPC) standards.
Inventive Step:
The invention must involve an inventive step, meaning it cannot be obvious to someone skilled in the field. The EPO’s problem-solution approach applies, assessing whether the invention provides a technical advance over existing knowledge.
Industrial Applicability:
The invention must be capable of practical application in industry. Biopharmaceuticals must demonstrate utility, such as therapeutic efficacy or manufacturing process advantages.
Excluded Subject Matter:
Portugal excludes from patentability inventions that concern methods of treatment of the human or animal body, diagnostic methods, and certain biological material per Article 53 of the EPC. However, claims related to new active compounds, formulations, or manufacturing processes remain eligible.
Enforceability of Biopharmaceutical Patents
Validity Checks:
Enforceability hinges on the patent's validity. Challenges often involve opposition procedures, validity revocation claims, or non-infringement defenses. Validity can be contested on grounds like invalidity of novelty, inventive step, or insufficient disclosure.
Standard of Proof:
In enforcement actions, the patent owner must establish the patent’s validity, while the defendant can raise defenses such as prior art or insufficiency.
Expiration and Maintenance:
Patents generally last 20 years from the application filing date, provided maintenance fees are paid. Non-payment can lead to patent lapse.
Data Exclusivity:
Biopharmaceuticals benefit from data exclusivity periods under EU law, which can delay generic approval even if patent protection lapses.
Scope of Claims
Claims Drafting:
Claims define the legal scope. In Portugal, claims for biopharmaceuticals often include:
- Compound claims: Covering chemical entities or biological molecules.
- Composition claims: Covering formulations or combinations.
- Process claims: Covering methods of production or use.
Claim Types:
- Product-by-Process Claims: Cover the product as defined by its manufacturing process.
- Swiss-Style Claims: Often used for polymorphs or specific formulations.
- Use Claims: Cover new therapeutic applications of known compounds.
Claim Strategy:
Claims should balance breadth and specificity. Broad claims improve enforceability but risk invalidation over prior art. Narrow claims provide clearer infringement boundaries but offer limited protection.
Claim Limitations:
Portuguese patent law emphasizes clarity and support. Claims must be fully supported by the description, including enablement and written description.
Summary Table: Patentability & Scope in Portugal
| Aspect |
Details |
| Novelty |
Must be new; prior art searches include EPO, WIPO |
| Inventive Step |
Non-obvious; assessed via EPO problem-solution approach |
| Industrial Applicability |
Must be capable of industrial use |
| Exclusions |
Methods of treatment, diagnostic methods, naturally occurring biological material |
| Enforcement |
Validity challenges, 20-year term, maintenance fees |
| Claim Scope |
Product, process, use claims; drafting balance ensures enforceability |
Key Takeaways
- Portugal follows EPC standards, emphasizing novelty, inventive step, and industrial application.
- Exclusions limit patentability for certain biological and medical methods.
- Validity defenses such as prior art can challenge enforceability.
- Clear, supported claims shape enforceability; broad claims face higher invalidation risks.
- Patent maintenance is critical for enforceability, with a 20-year term from filing date.
FAQs
Q1. How does Portugal handle patent term extension for biopharmaceuticals?
Patent term generally extends 20 years from filing. Supplementary protections like data exclusivity can delay generic entry but do not extend patent life.
Q2. Are there special procedures for biotech inventions?
No, Portugal applies standard EPC criteria. However, applicants should ensure biological materials are described fully and enable reproduction.
Q3. Can claims for secondary uses of known drugs be patented in Portugal?
Yes, use claims for new therapeutic indications are patentable if they meet all criteria and are supported by sufficient disclosure.
Q4. What are common grounds for patent invalidation in Portugal?
Prior art disclosures, lack of inventive step, insufficient disclosure, or claims not supported by description.
Q5. How important is claim drafting in patent enforceability?
Critical. Well-drafted claims that accurately reflect the invention's scope and are supported by the description improve enforceability and reduce invalidation risk.
Sources:
[1] European Patent Convention (EPC), 1973; Law No. 3/2013 on Patents in Portugal.
